Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CIBC World Markets Downgrades JNJ

Johnson & Johnson (JNJ) shares fell Wednesday even though the Food and Drug Administration said it supported approval for the Cypher drug-coated coronary stent made by JNJ's Cordis unit. CIBC World Markets downgraded JNJ shares to sector perform from sector outperform.

Analyst Mara Goldstein says the FDA approval confirms the EPS picture is bright, but JNJ's shares already reflect this. She says the panel stopped short of recommending Cypher be initially approved in lesion, artery lengths, but diameters were not part of SIRUS trial inclusion criteria. She believes this encompasses more than 60% of the stent market.

The company's biggest issue, Cypher's launch, comes as it needed to hide cracks in drug business and gain a lead on competitors. Although the fundamentals are solid, the shares are expensive, Goldstein says.

blog comments powered by Disqus